Clinical Intervention Increases Rational Use of Proton Pump Inhibitors in the General Surgery Department

• DOI: 10.3389/fphar.2022.864081
• Publication Date: 2022-04-25T14:38:02Z
• Authors: Qiying Chen; Qiaohong Wang; Yin Zhang
• Keywords: Pharmacology; 03 medical and health sciences; 0302 clinical medicine; PDCA cycle; pareto chart; Therapeutics. Pharmacology; RM1-950; proton pump inhibitors; clinical pharmacist; costeffectiveness analysis; 3. Good health

This study aimed to evaluate the role of clinical pharmacist in rational use proton pump inhibitors (PPIs) a general surgery department. All enrolled patients had attended department tertiary hospital. single-center prospective compared differences overall rate PPI use, proportion unindicated utilization rate, average defined daily dose (DDD), drug costs, and cost-effectiveness intervention between (538 cases) control (536 groups. In group, Pareto fishbone diagram analyses were combined with Plan-Do-Check-Act cycle; Statistical Package for Social Sciences was used analyzing all data. The significantly higher group than ( p < 0.01). DDD, costs lower 0.05). Cost-effectiveness analysis indicated positive impact intervention, economic benefits group. Clinical PPIs departments could increase use; it also reduce rates, DDDs, costs. Pharmacist offers by improving use.